RTA Laboratuvarlari Biyolojik (IS:RTALB) — Market Cap & Net Worth
Market Cap & Net Worth: RTA Laboratuvarlari Biyolojik (RTALB)
RTA Laboratuvarlari Biyolojik (IS:RTALB) has a market capitalization of $37.07 Million (TL1.66 Billion) as of May 8, 2026. Listed on the IS stock exchange, this Turkey-based company holds position #22971 globally and #408 in its home market, demonstrating a -11.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying RTA Laboratuvarlari Biyolojik's stock price TL3.31 by its total outstanding shares 500000000 (500.00 Million). Analyse RTALB cash generation efficiency to see how efficiently the company converts income to cash.
RTA Laboratuvarlari Biyolojik Market Cap History: 2015 to 2026
RTA Laboratuvarlari Biyolojik's market capitalization history from 2015 to 2026. Data shows growth from $12.91 Million to $37.07 Million (10.11% CAGR).
RTA Laboratuvarlari Biyolojik Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how RTA Laboratuvarlari Biyolojik's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.02x
RTA Laboratuvarlari Biyolojik's market cap is 1.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.11x
RTA Laboratuvarlari Biyolojik's market cap is 3.11 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $12.91 Million | $33.68 Million | $7.48 Million | 0.38x | 1.73x |
| 2016 | $9.00 Million | $31.81 Million | $4.09 Million | 0.28x | 2.20x |
| 2017 | $12.39 Million | $38.45 Million | $4.16 Million | 0.32x | 2.98x |
| 2018 | $7.81 Million | $20.47 Million | $601.21K | 0.38x | 12.99x |
| 2019 | $11.16 Million | $16.77 Million | $4.42 Million | 0.67x | 2.52x |
| 2020 | $145.71 Million | $230.44 Million | $60.93 Million | 0.63x | 2.39x |
| 2021 | $106.54 Million | $384.34 Million | $114.47 Million | 0.28x | 0.93x |
| 2022 | $145.47 Million | $86.03 Million | $281.12 Million | 1.69x | 0.52x |
| 2023 | $160.59 Million | $138.51 Million | -$103.16 Million | 1.16x | N/A |
| 2024 | $162.49 Million | $158.59 Million | $52.23 Million | 1.02x | 3.11x |
Competitor Companies of RTALB by Market Capitalization
Companies near RTA Laboratuvarlari Biyolojik in the global market cap rankings as of May 8, 2026.
Key companies related to RTA Laboratuvarlari Biyolojik by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $108.50 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $74.92 Billion USD.
- UCB SA (BR:UCB): Ranked #513 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #572 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $108.50 Billion | $427.65 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.92 Billion | $721.05 |
| #513 | UCB SA | BR:UCB | $51.74 Billion | €236.00 |
| #572 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
RTA Laboratuvarlari Biyolojik Historical Marketcap From 2015 to 2026
Between 2015 and today, RTA Laboratuvarlari Biyolojik's market cap moved from $12.91 Million to $ 37.07 Million, with a yearly change of 10.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | TL37.07 Million | -3.50% |
| 2025 | TL38.41 Million | -76.36% |
| 2024 | TL162.49 Million | +1.19% |
| 2023 | TL160.59 Million | +10.39% |
| 2022 | TL145.47 Million | +36.54% |
| 2021 | TL106.54 Million | -26.88% |
| 2020 | TL145.71 Million | +1205.19% |
| 2019 | TL11.16 Million | +42.90% |
| 2018 | TL7.81 Million | -36.95% |
| 2017 | TL12.39 Million | +37.66% |
| 2016 | TL9.00 Million | -30.26% |
| 2015 | TL12.91 Million | -- |
End of Day Market Cap According to Different Sources
On May 7th, 2026 the market cap of RTA Laboratuvarlari Biyolojik was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $37.07 Million USD |
| MoneyControl | $37.07 Million USD |
| MarketWatch | $37.07 Million USD |
| marketcap.company | $37.07 Million USD |
| Reuters | $37.07 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About RTA Laboratuvarlari Biyolojik
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S. engages in the research, development, and production of microbiology and molecular biology products in Turkey. It offers microbiology products, including petri dish, tube and bottle, chromogenic media, blood culture bottle, tuberculosis diagnostic, rapid test, microbiological stain, hygislide, surcheck media, membrane, paint… Read more